- The EMBRACE test is intended to offer an alternative to traditional preimplantation genetic testing via biopsy.
- It falls under the category of noninvasive preimplantation genetic testing.
- Studies have yielded widely varying results regarding this test.
- There is currently no independent, general recommendation for the EMBRACE test.
If you’re currently on your journey to start a family and would love nothing more than a single successful fertilization cycle, you may have already come across the so-called EMBRACE test from Igenomix©. The test promises groundbreaking new options for selecting and screening embryos before they are transferred. But what’s really behind this so-called “miracle test,” and is it even worth it for you? Here, we’ll look at critical and up-to-date studies to help you make a decision.
What is the EMBRACE test?
The EMBRACE test from Igenomix© is a test designed to analyze the DNA—that is, the genetic material—of embryos prior to embryo transfer. Based on these results, the healthiest and best-developed embryos are then selected and transferred. Up to this point, the concept is not new and is indistinguishable from the better-known preimplantation genetic diagnosis (PGD). What sets the EMBRACE test apart, therefore, is not its overall accuracy but its fundamental method of operation: In traditional preimplantation genetic diagnosis, small biopsies—that is, cell samples—are taken from the embryos. These biopsies are an invasive procedure. In contrast, the EMBRACE test is non-invasive. To analyze the embryo’s genetic material nonetheless, the test uses extracellular DNA that the embryo releases into its culture medium over the course of several days. The DNA analyzed by the EMBRACE test is thus secreted by the embryo and is, so to speak, freely available. The company Igenomix© aims to offer an alternative to traditional preimplantation genetic diagnosis. This approach, known as the EMBRACE test, falls under the category of non-invasive preimplantation genetic diagnosis (EMBRACE Hub, 2026).
Both traditional preimplantation genetic diagnosis and the EMBRACE test are designed to detect chromosomal abnormalities (more specifically, aneuploidies)—that is, errors in the number of chromosomes in the genetic material—and thus identify embryos with certain genetic defects even before implantation.
It is important to note, however, that neither preimplantation genetic testing nor the EMBRACE test can guarantee a successful pregnancy or a healthy child. They can only help weigh or compare risks and chances.
Can the EMBRACE test detect aneuploidies at all?
While the EMBRACE test sounds incredibly promising and exciting, it is, of course, essential to know whether the test is actually capable of reliably detecting genetic variations. After all, some things are just too good to be true.
To answer this question, the test results of non-invasive preimplantation genetic testing (PGT), such as the EMBRACE test, were compared with those of traditional invasive PGT. Unfortunately, the results were quite mixed.
In 2018, a study was conducted that made precisely this comparison. This study was supported by Igenomix©, the manufacturer of the EMBRACE test. The study authors found that approximately 67% of the test results from non-invasive preimplantation genetic testing differed from those of invasive preimplantation genetic testing. Subsequent investigations then revealed that in three out of four cases where the test results differed, the invasive, traditional preimplantation genetic testing was correct. The scientists attributed the failure of methods such as the EMBRACE test to contamination of the embryo’s extracellular DNA by maternal DNA (Vera-Rodriguez, M., et al., 2018).
This year, two similar studies on this topic were conducted again. One of the two studies was also conducted in connection with Igenomix© itself. As part of this very study, it was found that approximately 79% of the test results from non-invasive preimplantation genetic testing matched those from invasive preimplantation genetic testing. This could be due to further refinements of the methods used in 2018 (Navarro-Sánchez, L., et al., 2026).
Unfortunately, the recent study—which is unrelated to Igenomix©—paints a very different picture of the test results: The authors of this study, which is independent of Igenomix©, report that non-invasive preimplantation genetic testing detected only about 54% of aneuploidies compared to invasive preimplantation genetic testing (Satirapod, C., et al., 2026). It should be noted, however, that this study—which yielded rather sobering results—was conducted at different stages of embryo culture than the other studies. Consequently, the embryos had not spent the same amount of time in the culture medium.
Does the EMBRACE test increase the chances of a successful pregnancy?
Aside from the question of whether testing methods like the EMBRACE test are even capable of detecting genetic variations, the chance of having a healthy baby is likely the most important factor for you and your journey to parenthood.
First Study
A study, also conducted in collaboration with Igenomix©, compared embryo selection based solely on morphology versus non-invasive preimplantation genetic testing such as the EMBRACE test. Morphological assessment is a method that has been used for decades to evaluate, among other things, the cell count and shape of the embryo. However, it cannot provide any information about the embryo’s genetics and thus differs significantly from invasive preimplantation genetic testing.
In a single cycle of in vitro fertilization, the probability of a clinical pregnancy in cases of recurrent implantation failure and with a purely morphological assessment of the embryo was just under 29%. When non-invasive preimplantation genetic testing was used instead to assess the embryos, a clinical pregnancy rate of just under 47% was achieved. The continued pregnancy rate among women with recurrent miscarriages was 25% with purely morphological assessment and approximately 41% with the use of non-invasive preimplantation genetic testing. The conclusion reached by the study authors was therefore positive (Bakalova, D. N., et al., 2025).
Second Study
Another study also investigated whether non-invasive preimplantation genetic testing or the traditional morphological assessment of embryos is more beneficial. This study was conducted in 2026 independently of Igenomix© or other pharmaceutical companies. Unfortunately, the scientists involved in this study reached less positive conclusions: They found no significant difference between the two methods in terms of clinical pregnancy rates, miscarriage rates, and live birth rates. Only the risk of early miscarriage was reduced in this study through the use of non-invasive preimplantation genetic testing. The experts who conducted this study therefore do not generally recommend non-invasive preimplantation genetic testing. However, they point out that in some cases, it may be advisable to use non-invasive preimplantation genetic testing. The women who participated in this study were all between the ages of 35 and 42 (Huang, J., et al., 2026).
EMBRACE Test for Frozen Embryos
For some couples, using frozen and thawed embryos may be more appropriate than using “fresh” embryos for various reasons. Of course, frozen and thawed embryos can also be screened using preimplantation genetic testing. Researchers have even found that non-invasive preimplantation genetic testing, such as the EMBRACE test, yields better results with frozen and thawed embryos than with “fresh” embryos. Specifically, the test is significantly more likely to correctly detect and identify aneuploidies. This can significantly alter and influence the selection of embryos that are transferred. In this study, non-invasive preimplantation genetic testing generally yielded very good results. This study is not related to Igenomix© (Wen, X., et al., 2026).
Where do the differences in test results come from?
In the course of our research, we gradually noticed that test results from studies related to Igenomix© often show better outcomes than those conducted independently of the company. You may have noticed this as well while reading this article.
So, has Igenomix© had studies doctored?
No, we do not believe that at all, and we certainly do not want to give that impression! Even the studies directly associated with the manufacturers of the EMBRACE test were certainly conducted to the highest quality standards and in an honest manner. But where does the difference come from, then? Each study is conducted under different conditions, which can significantly influence the results. Not all measurements were taken at the same stage of embryo development, and the quality of the embryos used in the various studies certainly varies as well. Furthermore, the circumstances and medical histories of the women and men from whom the eggs and sperm used to create the embryos were obtained were most likely not the same across all studies. It’s also possible that laboratory conditions, the staff conducting the tests, or other external factors play a decisive role in the discrepancies between different studies.
Studies can thus be fundamentally influenced, whether consciously or unconsciously; however, we do not view this as a criticism or accusation against specific individuals, companies, or studies, but simply wish to provide this information.
It was simply important to us to objectively point out which studies are associated with a company that has its own interests in this area and which are not. From our perspective, this is about transparency and openness, which should make it easier for you to make an informed decision regarding non-invasive preimplantation genetic testing. It is by no means intended as a criticism or accusation against companies or individuals who were involved in any of the studies mentioned.
So, is the EMBRACE test recommended?
As they say, the best is saved for last, and with this question, you’ve hit the nail on the head. Unfortunately, from our perspective, it’s not possible to give you a definitive answer to this question. Ultimately, it’s fair to say that the EMBRACE test may offer an advantage in certain cases. This depends on many factors—not least of which is what alternative testing options are available. Of course, all decisions regarding assisted reproduction also involve your personal views and preferences, which always play a major role in such a private and sensitive matter. A combination of invasive and non-invasive preimplantation genetic testing might also be a good option—or it might not. As unsatisfying as that may sound, we strongly urge you to seek advice from a specialist to get to the bottom of this question as you embark on your journey to start a family. Of course, you should—and must—be prepared for such a consultation and be able to ask critical questions. With that in mind, we sincerely hope that this article can be of at least a little help to you.
Frequently Asked Questions on This Topic
What distinguishes the EMBRACE test from traditional preimplantation genetic testing (PGT)?
Traditional PGT is an invasive procedure in which cells are removed from the embryo via biopsy. The EMBRACE test is a non-invasive method (niPGT-A) that instead analyzes cell-free DNA released by the embryo into the culture medium.
Can the EMBRACE test guarantee a healthy baby?
No. Neither traditional PGT nor the EMBRACE test can guarantee a successful pregnancy or a healthy child. They primarily serve as a selection tool to better assess genetic risks before embryo transfer.
Why do the results of the EMBRACE test differ from those of conventional PGT?
One main reason is the potential contamination of the cell-free DNA in the culture medium by maternal cells. In addition, the exact timing of sample collection and the duration of cultivation in the laboratory play a decisive role.
Does the EMBRACE test increase the chances of success with in vitro fertilization?
Some studies show higher clinical pregnancy rates with embryo selection using niPGT-A. However, independent studies have often failed to find a significant difference in live birth rates compared to conventional morphological assessment.
Can the EMBRACE test be used with frozen embryos?
Yes. Studies show that non-invasive preimplantation genetic testing on thawed embryos sometimes yields more reliable results than on fresh embryos, since aneuploidies can be detected more accurately in the culture medium.
Why do manufacturer-funded studies often yield more positive results than independent studies?
This is usually due to differences in study conditions (e.g., timing of laboratory procedures, quality requirements for micromanipulation, or patient selection) and not necessarily due to data manipulation.
For whom is the EMBRACE test ultimately recommended?
The test can serve as an additional decision-making tool in individual cases—such as in cases of recurrent implantation failure or following miscarriages. Whether the method is appropriate should always be decided in consultation with the treating reproductive medicine specialists.
References
- Vitrolife, Igenomix©. EMBRACE Hub (n.d.). Retrieved October 14, 2026, from https://www.igenomix.eu/embrace_hub/
- Vera-Rodriguez, M., Diez-Juan, A., Jimenez-Almazan, J., Martinez, S., Navarro, R., Peinado, V., Mercader, A., Meseguer, M., Blesa, D., Moreno, I., Valbuena, D., Rubio, C., & Simon, C. (2018). Origin and composition of cell-free DNA in spent medium from human embryo culture during preimplantation development. Human reproduction (Oxford, England), 33(4), 745–756. https://doi.org/10.1093/humrep/dey028
- Navarro-Sánchez, L., Sakkas, D., Frantz, N., Lucena, E. F., Venier, W., Soscia, D. M., Barroso, G., Bisioli, C., DiMattina, M., Teke, B., Escudero, L. E., & Rubio, C. (2026). Can Cell-Free DNA in the Culture Medium Predict the Chromosomal Constitution of Preimplantation Embryos? Final Results from a Multicenter Study with 2539 Blastocysts. Genes, 17(4), 416. https://doi.org/10.3390/genes17040416
- Satirapod, C., Niransuk, P., Tantanavipas, S., Sensorn, I., Chantratita, W., & Trachoo, O. (2026). Application of non-invasive preimplantation genetic screening for aneuploidy through spent embryo culture media analysis at 48 and 54 hours after embryo cleavage. British journal of biomedical science, 83, 15905. https://doi.org/10.3389/bjbs.2026.15905
- Bakalova, D. N., Navarro-Sánchez, L., & Rubio, C. (2025). Non-Invasive Preimplantation Genetic Testing. Genes, 16(5), 552. https://doi.org/10.3390/genes16050552
- Huang, J., Li, R., Zeng, L., Hu, L., Cai, L., Chen, L., Shi, J., Wang, Y., Guan, Y., Xu, Y., Qian, W., Wang, X., Xi, H., Zhao, Z., Yao, Y., Lu, S., Yao, Y., Wang, J., Liu, P., & Qiao, J. (2026). Embryo selection by non-invasive preimplantation genetic testing for aneuploidy in women of advanced maternal age: a randomized, clinical trial. Nature communications, 17(1), 10634. https://doi.org/10.1038/s41467-026-77628-4
- Wen, X., Huo, J., Ou, Z., Lin, X., Ke, W., Lyu, Y., Li, Q., Zhang, X., & Li, Z. (2026). Comparative study of noninvasive chromosomal screening using blastocyst culture media: frozen-thawed embryos outperform fresh embryos. Frontiers in endocrinology, 17, 1851046. https://doi.org/10.3389/fendo.2026.1851046




















